These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Comparison of 6- and 12-core prostate biopsy in Taiwanese men: impact of total prostate-specific antigen, prostate-specific antigen density and prostate volume on prostate cancer detection.
    Author: Chiang IN, Chang SJ, Pu YS, Huang KH, Yu HJ, Huang CY.
    Journal: Urol Int; 2009; 82(3):270-5. PubMed ID: 19440012.
    Abstract:
    INTRODUCTION: We retrospectively compared 6- and 12-core prostate biopsies in Taiwanese men and evaluated the impact of prostate volume (PV), prostate-specific antigen (PSA), and PSA density (PSAD) on the prostate cancer detection rate (PCDR). PATIENTS AND METHODS: 1,086 consecutive patients with a total PSA of 4.1-20.0 ng/ml and/or abnormal digital rectal examination undergoing first-time transrectal ultrasound-guided biopsy were included. Group I patients (n = 562) underwent sextant biopsy and group II patients (n = 524) underwent sextant biopsy with an extra three lateral cores on both sides. The patients were further stratified into subgroups according to PV (cut-off: 35 ml), PSA (cut-off: 10.0 ng/ml), and PSAD (cut-off: 0.2). RESULTS: Prostate cancer was diagnosed in 228/1,086 (21.0%) patients. The PCDR was higher in group II (23.7%) than group I (18.5%). 12-Core biopsy yielded a significantly higher PCDR than 6-core biopsies in patients with PV >35 ml, PSA 4.1-10.0 ng/ml, PSAD <or=0.20, but not in patients with PV <or=35 ml, PSA 10.1-20.0 ng/ml, PSAD >0.20. CONCLUSIONS: 12-Core biopsy yielded a significantly higher PCDR in Taiwanese men with a total PSA of 4.1-20.0 ng/ml, especially in patients with PSA 4.1-10.0 ng/ml, PSAD <or=0.20, and PV >35 ml.
    [Abstract] [Full Text] [Related] [New Search]